MPN stands for myeloproliferative neoplasm, a group of rare, chronic blood cancers in which the bone marrow makes too many blood cells. The three main MPNs are polycythemia vera (too many red blood cells), essential thrombocythemia (too many platelets), and myelofibrosis (scarring of the bone marrow). While there is currently no widely accepted cure, many patients live for decades with proper treatment and monitoring.
MPNs develop when blood-producing stem cells in the bone marrow acquire a mutation, most commonly in the JAK2 gene, that signals the marrow to keep making blood cells the body does not need. The World Health Organization classifies MPNs as blood cancers, although they behave differently from most cancers: they are chronic conditions managed over years rather than treated in a single course.
This guide explains what an MPN diagnosis means, the symptoms the three diseases share, how MPNs are diagnosed and treated, and where to find an MPN specialist.
The Three Main Types of MPN
MPNs are categorized by which blood cell line is predominantly affected. The three classic myeloproliferative neoplasms are polycythemia vera, essential thrombocythemia, and myelofibrosis.
Polycythemia Vera (PV)
Polycythemia vera causes the bone marrow to make too many red blood cells, and often excess white blood cells and platelets as well. The extra cells thicken the blood, which raises the risk of blood clots and causes symptoms such as headaches, dizziness, and itching (especially after a warm shower). About 95 to 97 percent of PV patients carry a JAK2 mutation.
Essential Thrombocythemia (ET)
Essential thrombocythemia causes the bone marrow to produce too many platelets, the cell fragments responsible for clotting. Many ET patients have no symptoms at diagnosis and discover the condition through a routine blood test. The main risks are abnormal clotting and, less commonly, bleeding.
Myelofibrosis (MF)
Myelofibrosis is the scarring (fibrosis) of the bone marrow, which crowds out healthy blood-producing cells. It can develop on its own (primary myelofibrosis) or progress from PV or ET. Common signs include anemia, fatigue, and an enlarged spleen. MF is generally the most serious of the three main MPNs and the one most likely to require advanced treatment.
Common MPN Symptoms
Because the three MPNs share the same overactive signaling pathway, they share many symptoms. The most commonly reported include:
- Fatigue, the most frequent symptom across all three diseases
- Headaches and dizziness
- Itching (pruritus), often triggered by warm water
- Night sweats
- Bone and joint pain
- Difficulty concentrating, often described as brain fog
- Feeling full quickly or abdominal discomfort, caused by an enlarged spleen
Symptom severity varies widely from patient to patient, and research shows that doctors often underestimate the symptom burden their MPN patients experience. Tracking your symptoms and reporting them clearly at appointments is one of the most useful things you can do for your own care.
Disease Risks to Know About
Beyond daily symptoms, MPNs carry longer-term risks that your care team monitors: blood clots or abnormal bleeding (the most important risk in PV and ET), gradual scarring of the bone marrow, and in a small percentage of patients, progression to acute myeloid leukemia. Progression risk differs by disease and is highest in myelofibrosis, which is why regular monitoring matters even when you feel well.
What Causes MPNs?
MPNs are driven by acquired genetic mutations in the blood-forming stem cells of the bone marrow. Acquired means you are not born with the mutation; it develops during your lifetime. Three driver mutations account for the large majority of MPN cases:
- JAK2 (Janus kinase 2): discovered in 2005, found in about 95 percent of polycythemia vera cases and roughly half of ET and MF cases
- CALR (calreticulin): the second most common driver, seen mainly in ET and MF
- MPL: a less common driver mutation, also seen in ET and MF
These mutations all converge on the same problem: overactivation of the JAK-STAT signaling pathway. This pathway normally controls how blood cells are produced, mature, and die off. When it is stuck in the “on” position, the bone marrow overproduces blood cells, which is the defining feature of an MPN. Some patients have no identifiable driver mutation but still show this same pathway overactivation.
MPNs are not typically inherited. In most cases they occur spontaneously, with the risk increasing with age. A small number of families do show a higher tendency to develop MPNs, but this is the exception rather than the rule.
How Are MPNs Diagnosed?
MPNs are often discovered by accident, when a routine blood test shows counts that are higher than expected. Confirming which MPN a patient has usually involves several steps:
- Complete blood count (CBC): measures red blood cells, white blood cells, and platelets, and is typically the first sign that something is off
- Molecular testing: a blood test that checks for the JAK2, CALR, and MPL driver mutations
- Bone marrow biopsy: examines the marrow directly for cell overproduction and for scarring (fibrosis), and is the most reliable way to distinguish between ET, early myelofibrosis, and other conditions
- Additional bloodwork: tests such as erythropoietin (EPO) levels help separate polycythemia vera from other causes of elevated red blood cell counts
Diagnosis follows criteria set by the World Health Organization, which combine blood counts, mutation status, and bone marrow findings. Because MPNs are rare, an accurate diagnosis often depends on who is reading the results. Many community hematologists see only a handful of MPN patients in a career, which is why a second opinion from an MPN specialist is worth pursuing, particularly when the diagnosis is unclear or the recommended treatment plan is aggressive.
If you have been recently diagnosed and are unsure what to ask at your next appointment, our list of questions to ask your doctor is a useful starting point.
How Are MPNs Treated?
There is currently no widely accepted cure for MPNs, with the exception of allogeneic stem cell transplant, which is potentially curative but carries serious risks. Treatment goals therefore focus on reducing the risk of blood clots, controlling blood counts, easing symptoms, and slowing disease progression. The right approach depends on which MPN you have, your risk category, your age, and your symptoms.
Watchful Waiting
Low-risk patients, particularly those with essential thrombocythemia, may not need active treatment right away. Monitoring blood counts and symptoms on a regular schedule is a legitimate treatment plan, not a lack of one.
Phlebotomy and Low-Dose Aspirin
For polycythemia vera, removing blood (phlebotomy) to lower the red blood cell count, combined with low-dose aspirin, is standard first-line care. The usual target is a hematocrit below 45 percent, a threshold shown to reduce cardiovascular events.
Cytoreductive Medications
Patients at higher risk may be prescribed medication to reduce blood cell production. Hydroxyurea is the most commonly used first-line option. Pegylated interferons are another established choice, including Besremi (ropeginterferon alfa-2b), which is FDA approved for polycythemia vera.
JAK Inhibitors
JAK inhibitors target the overactive JAK-STAT pathway directly. Jakafi (ruxolitinib) is approved for myelofibrosis and for polycythemia vera patients who cannot tolerate hydroxyurea. Other approved options for myelofibrosis include Vonjo (pacritinib), Ojjaara (momelotinib), and Inrebic (fedratinib).
Stem Cell Transplant
Allogeneic stem cell transplant is the only potentially curative treatment for MPNs. It is used selectively, generally in younger patients with advanced myelofibrosis, because the risks of the procedure often outweigh the benefits in chronic, well-managed disease.
Clinical Trials
New MPN treatments are in active development, and clinical trials give patients access to therapies not yet widely available. Our MPN Clinical Trial Finder can help you search for studies that match your diagnosis.
What This Means for You
An MPN diagnosis is serious, but it is not the emergency most people assume when they hear the word “cancer.” These are chronic diseases, managed over years and often decades. Many patients maintain normal life expectancy with appropriate treatment and monitoring, and treatment options have expanded substantially since the JAK2 discovery in 2005.
Two things matter most in the early stages. The first is getting an accurate diagnosis, since ET, early myelofibrosis, and secondary causes of high blood counts can look similar and carry different treatment paths. The second is being seen by someone who treats MPNs regularly. These are rare diseases, and experience makes a measurable difference in risk assessment and treatment selection.
Resources to Help You Take the Next Step
- MPN Specialist Directory: find a verified MPN specialist by state
- PV for Newbies: a starting guide for the newly diagnosed
- Questions to Ask Your Doctor: what to bring to your next appointment
- MPN Clinical Trial Finder: search open studies by diagnosis
- Financial Assistance Programs: help with treatment costs
- MPN Cancer Dictionary: plain-language definitions of terms you will hear
Frequently Asked Questions About MPNs
What does MPN stand for?
MPN stands for myeloproliferative neoplasm. The term describes a group of chronic blood cancers in which the bone marrow produces too many blood cells. The three main types are polycythemia vera, essential thrombocythemia, and myelofibrosis.
Is an MPN a form of cancer?
Yes. The World Health Organization classifies myeloproliferative neoplasms as blood cancers. They behave differently from most cancers, however: MPNs are chronic conditions managed over many years rather than treated in a single course, and many patients live for decades after diagnosis.
What is the life expectancy with an MPN?
Life expectancy varies by diagnosis and risk category. Many patients with polycythemia vera or essential thrombocythemia have a near-normal life expectancy when the disease is well managed. Myelofibrosis generally carries a shorter prognosis, though outcomes differ widely depending on risk score, age, and response to treatment. Your specialist can explain where you fall using established risk scoring systems.
Are MPNs hereditary?
MPNs are usually not inherited. The driver mutations that cause them, including JAK2, CALR, and MPL, are acquired during a person’s lifetime rather than passed down. A small number of families do show a higher tendency to develop MPNs, but most cases occur spontaneously and risk increases with age.
Can one MPN turn into another?
Yes. Polycythemia vera and essential thrombocythemia can progress to myelofibrosis over time, and a small percentage of MPN patients progress to acute myeloid leukemia. Progression is not inevitable, and regular monitoring allows your care team to detect changes early.
What is the difference between an MPN and leukemia?
Both are blood cancers that begin in the bone marrow, but they behave differently. MPNs are chronic and typically progress slowly over years, with the marrow overproducing mature blood cells. Acute leukemia progresses rapidly and involves the buildup of immature cells. A small percentage of MPN patients eventually progress to acute myeloid leukemia, which is why ongoing monitoring is part of standard MPN care.
